Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)

The U.S.

Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.'s (NYSE:BMY) investigational oral therapy mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.

The agency assigned a Prescription Drug User Fee Act target action date of May 13, 2027, with the filing supported by positive Phase 3 SUCCESSOR-2 trial results. • Bristol-Myers Squibb stock is building positive momentum.

Why are BMY shares climbing?

FDA Accepts Mezigdomide Application Mezigdomide is an oral cereblon E3 ligase modulator (CELMoD), being developed to treat multiple myeloma.